Pharmacological profile of neuroleptics at human monoamine transporters

European Journal of Pharmacology

Volumn 368, Issue 2-3, 1999, Pages 277-283

  Tatsumi, Masahiko ^a,b   Jansen, Karen ^a   Blakely, Randy D ^c   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT (5 hydroxy hyptamine, serotonin), human; Dopamine transporter, human; Neuroleptic; Norepinephrine transporter, human; Radioligand binding assay

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; CHLORPROMAZINE; CHLORPROTHIXENE; DOPAMINE TRANSPORTER; FLUPERLAPINE; HALOPERIDOL; IMIPRAMINE; LOXAPINE; MELPERONE; MESORIDAZINE; MOLINDONE; MONOAMINE; MOPERONE; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; NISOXETINE; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN TRANSPORTER; SERTINDOLE; SULTOPRIDE; TIMIPERONE; TIOSPIRONE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; ZIPRASIDONE; ZOTEPINE;

ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG INTERACTION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PSYCHOSIS; RADIOASSAY;

ANTIPSYCHOTIC AGENTS; CARRIER PROTEINS; CELL LINE; CHLORPROMAZINE; COCAINE; DIBENZAZEPINES; DIBENZOTHIEPINS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FLUOXETINE; HUMANS; IMIPRAMINE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PIMOZIDE; PIPERAZINES; PROTEIN BINDING; RADIOLIGAND ASSAY; RECOMBINANT FUSION PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPORTERS; THIAZOLES; TRIFLUPROMAZINE; TRITIUM;

EID: 0032979135     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00005-9     Document Type: Article

References (36)

1. Barker E.L., Blakely R.D. Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol. Pharmacol. 50:1996;957-965.
2. Barker E.L., Kimmel H.L., Blakely R.D. Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Mol. Pharmacol. 46:1994;799-807.
3. Bolden-Watson C., Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
4. 3H] imipramine indicates the presence of a specific serotonin transport system on endothelial cells of porcine brain Neurosci. Lett. 194:1995;21-24.
5. Bylund, D.B., Yamamura, H.I., 1990. Methods for receptor binding. In: Yamamura, H.I., Enna, S.J., Kuhar, M.J. (Eds.), Methods in Neurotransmitter Receptor Analysis. Raven Press, New York, NY, pp. 1-35.
6. Chen C., Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell Biol. 7:1987;2745-2752.
7. De Lean A., Hancock A.A., Lefkowitz R.J. Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol. Pharmacol. 21:1982;5-16.
8. Eshleman A.J., Neve R.L., Janowsky A., Neve K.A. Characterization of a recombinant human dopamine transporter in multiple cell lines. J. Pharmacol. Exp. Ther. 274:1995;276-283.
9. Feinberg S.S., Kay S.R., Elijovich L.R., Fiszbein A., Opler L.A. Pimozide treatment of the negative schizophrenic syndrome: an open trial. J. Clin. Psychiatry. 49:1988;235-238.
10. Fink M., Klein D.F., Kramer J.C. Clinical efficacy of chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders. Psychopharmacologia. 7:1965;27-36.
11. Fleming W.W., Westfall D.P., De La Lande I.S., Jellett L.B. Log-normal distribution of equieffective doses of norepinephrine and acetylcholine in several tissues. J. Pharmacol. Exp. Ther. 181:1972;339-345.
12. 3H] nisoxetine binding in rat brain J. Neurochem. 64:1995;2792-2800.
13. Haggendal J., Hamberger B. Quantitative in vitro studies on noradrenaline uptake and its inhibition by amphetamine, desipramine and chlorpromazine. Acta Physiologica Scandinavica. 70:1967;277-280.
14. Jayanthi L.D., Prasad P.D., Ramamoorthy S., Mahesh V.B., Leibach F.H., Ganapahy V. Sodium- and chloride-dependent, cocaine-sensitive, high-affinity binding of nisoxetine to the human placental norepinephrine transporter. Biochemistry. 32:1993;12178-12185.
15. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry. 153:1996;466-476.
16. Klein, D.F., Davis, J.M., 1969. Diagnosis and Drug Treatment of Psychiatric Disorders. The Williams and Wilkins, Baltimore.
17. Kolivakis T., Azim H., Kingstone E. A double-blind comparison of pimozide and chlorpromazine in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental. 16:1974;998-1004.
18. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
19. Madras B.K., Fahey M.A., Bergman J., Canfield D.R., Spealman R.D. Effects of cocaine and related drugs in nonhuman primates. J. Pharmacol. Exp. Ther. 251:1989;131-141.
20. i values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
21. Munson P.J., Rodbard D. LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107:1980;220-239.
22. 3H] imipramine binding to the human platelet 5-hydroxytryptamine carrier: an explanation for the allosteric interaction between 5-hydroxytryptamine and imipramine J. Neurochem. 54:1990;1275-1280.
23. Pacholczyk T., Blakely R.D., Amara S.G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 350:1991;350-354.
24. Pfenning, M.A., Richelson, E., 1990. Methods for studying receptors with cultured cells of nervous tissue origin. In: Yamamura, H.I., Enna, S.J., Kuhar, M.J. (Eds.), Methods in Neurotransmitter Receptor Analysis. Raven Press, New York, pp. 147-175.
25. 3H] GBR 12,935 binding Mol. Pharmacol. 45:1994;125-135.
26. Ramamoorthy S., Bauman A.L., Moore K.R., Han H., Yang-Feng T., Chang A.S., Ganapathy V., Blakely R.D. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl. Acad. Sci. U.S.A. 90:1993;2542-2546.
27. Reith M.E., Xu C., Zhang L., Coffey L.L. Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter. Naunyn-Schmiedeberg's Arch. Pharmacol. 354:1996;295-304.
28. Richelson E. Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin. Proc. 69:1994;1069-1081.
29. Richelson E., Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur. J. Pharmacol. 104:1984;277-286.
30. Sallee F.R., Pollock B.G., Stiller R.L., Stull S., Everett G., Perel J.M. Pharmacokinetics of pimozide in adults and children with Tourette's syndrome. J. Clin. Pharmacol. 27:1987;776-781.
31. Sallee F.R., Nesbitt L., Jackson C., Sine L., Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder [see comments]. Am. J. Psychiatry. 154:1997;1057-1062.
32. Siris S.G., Bermanzohn P.C., Gonzalez A., Mason S.E., White C.V., Shuwall M.A. The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacology Bulletin. 27:1991;331-335.
33. Siris S.G., Bermanzohn P.C., Mason S.E., Shuwall M.A. Maintenance imipramine therapy for secondary depression in schizophrenia: a controlled trial. Arch. Gen. Psychiatry. 51:1994;109-115.
34. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340:1997;249-258.
35. 3H] nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding J. Pharmacol. Exp. Ther. 260:1992;427-436.
36. Van Putten T., Marder S.R., Wirshing W.C., Aravagiri M., Chabert N. Neuroleptic plasma levels. Schizophr. Bull. 17:1991;197-216.